ARID1A

Across TCGA pan-cancer cohorts, ARID1A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ARID1A’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ARID1A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARID1A is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LSCC, LUAD, and HNSC are the cancer types where ARID1A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARID1A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.302	<.001	9	view →
LUAD	Female	All	+0.239	<.001	9	view →
HNSC	Male	II,III,IV	+0.279	<.001	8	view →
COAD	Male	II,III,IV	+0.137	.001	5	view →
PDAC	Male	All	−0.249	.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ARID1A–LSCC

Open the LSCC breakdown →